Avid and Halozyme expand supply relationship
Avid Bioservices and Halozyme Therapeutics have expanded their relationship, adding manufacturing agreements and designating the CMO as a preferred supplier.
The new deal amends and expands commercial supply agreements for human hyaluronidase (rHuPH20) which is used in two of Halozyme’s products. Furthermore, the companies have entered into a new commercial supply agreement for additional rHuPH20 products.
Avid has also been designated as a preferred supplier of future Halozyme products which require the contract manufacturing organisation’s (CMO) process development and biomanufacturing capabilities and expertise.
"Expanding our commercial supply relationship with Avid is a testament to the strong relationship we have developed over the past five years", added Jonathan Lim, Halozyme's president and CEO.
